Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Arthritis & Rheumatology ; 01:01, 2022.
Article in English | MEDLINE | ID: covidwho-2148270

ABSTRACT

OBJECTIVE: COVID-19 associated pediatric vasculitis other than Kawasaki disease (KD)-like vasculitis in multisystem inflammatory syndrome in children (MIS-C) is very rare. We aimed to analyze the characteristics, treatment and outcome in COVID-19-associated pediatric vasculitis (excluding KD-like vasculitis in MIS-C).

3.
Annals of the Rheumatic Diseases ; 80(6):e95, 2021.
Article in English | MEDLINE | ID: covidwho-1909672
4.
Asian Pacific Journal of Tropical Medicine ; 15(4):171-178, 2022.
Article in English | CAB Abstracts | ID: covidwho-1855963

ABSTRACT

Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/ Pfizer) vaccine.

5.
Clinical Pediatric Endocrinology ; 31(1):33-37, 2022.
Article in English | Web of Science | ID: covidwho-1854916

ABSTRACT

The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo-18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61(52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.

6.
Hormone Research in Paediatrics ; 94(SUPPL 1):244-244, 2021.
Article in English | Web of Science | ID: covidwho-1441629
7.
Annals of the Rheumatic Diseases ; 80(SUPPL 1):908, 2021.
Article in English | EMBASE | ID: covidwho-1358860

ABSTRACT

Background: The severity of COVID-19 symptoms can range from mild to severe. Severe COVID-19 cases with excessive hyperinflammation have many overlap features with multisystem inflammatory syndrome in children (MIS-C). Objectives: We aimed to describe the typical clinical and laboratory features and treatment of children diagnosed with MIS-C and to understand the differences as compared to severe/critical pediatric cases with COVID-19 in an eastern Mediterranean country. Methods: Children (aged <18 years) who diagnosed with MIS-C and severe/ critical pediatric cases with COVID-19, were admitted to hospital between 26 March and 3 November 2020 were enrolled in the study. Results: A total of 52 patients, 22 patients diagnosed with COVID-19 with severe/critical disease course and 30 patients diagnosed with MIS-C. Although severe COVID-19 cases and cases with MIS-C share many clinical and laboratory features, MIS-C cases had longer fever duration and higher rate of the existence of rash, conjunctival injection, peripheral edema, abdominal pain, altered mental status, and myalgia than in severe cases (p<0.001 for each). Of all, 53.3% of MIS-C cases had the evidence of myocardial involvement as compared to severe cases (27.2%). Additionally, C-reactive protein (CRP) and white blood cell (WBC) are the independent predictors for the diagnosis of MIS-C, particularly in the existence of conjunctival injection and rash. Corticosteroids, intravenous immunoglobulin (IVIG), and biologic immunomodulatory treatments were mainly used in MIS-C cases rather than cases with severe disease course. There were only 3 deaths among 52 patients, one of whom had Burkitt lymphoma and the two cases with severe COVID-19 of late referral. Conclusion: Differences between clinical presentations, acute phase responses, organ involvements, and management strategies indicate that MIS-C might be a distinct immunopathogenic disease as compared to pediatric COVID-19. Conjunctival injection and higher CRP and low WBC count seem good diagnostic parameters for MIS-C cases.

8.
Minerva Pneumologica ; 59(3):49-54, 2020.
Article in English | Web of Science | ID: covidwho-914942

ABSTRACT

BACKGROUND: In March, we first hypothesized that;even though there was a higher number of COVID-19 patients in countries with a high population such as China, mortality rates in those countries were lower compared to other countries which do not have routine BCG vaccination. Therefore, we aimed to evaluate the accuracy of the hypothesis we made, by investigating the relationship of COVID-19 patients with BCG vaccine. METHODS: We retrospectively analyzed tuberculosis sequelae lesions and the presence of BCG vaccination in the radiological images and clinical reports of first fifty confirmed COVID-19 in-patients to evaluate our hypothesis in the shortest time. RESULTS: There was no pneumonia in 16 (32%) of patients. The mild, moderate and severe pneumonia ratios were 12 (24%), 10 (20%) and 12 (24%), respectively. Seven (1.4%) of the patients had respiratory failure and were followed up in the intensive care unit (ICU). Only one patient died during the follow-up time. CONCLUSIONS: We think that a considerably lower mortality rate, less severe course and more favorable prognosis of COVID-19 can be associated with the BCG vaccine. Current knowledge supports the utilization of a single-dose BCG vaccine to fight with this novel virus with its immunomodulatory properties, at least until the specific immunizations will be developed.

SELECTION OF CITATIONS
SEARCH DETAIL